

iCAD offers a range of high-performance expandable computer-aided detection systems to facilitate early detection of cancers. Among its major competitors, icad is ranked in 8th place for NPS while Veracyte is 1st, and Ventana Medical is 2nd.Their current market cap is $493.63M